Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review

被引:12
|
作者
Dakurah, Ottovon Bismark [1 ]
Tamandjou, Cynthia Raissa Tchuem [2 ]
Zunza, Moleen [3 ]
Preiser, Wolfgang [4 ]
Maponga, Tongai Gibson [4 ]
机构
[1] Stellenbosch Univ, Fac Med & Hlth Sci, African Canc Inst, Dept Global Hlth, Cape Town, South Africa
[2] Univ Cape Town, Sch Publ Hlth & Family Med, Div Hlth Econ, Cape Town, South Africa
[3] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Cape Town, South Africa
[4] Stellenbosch Univ, Fac Med & Hlth Sci, Div Med Virol, Cape Town, South Africa
关键词
Hepatocellular carcinoma; Hepatitis B virus; Hepatitis C virus; Hepatitis D virus; Africa; Sub-Saharan Africa; Direct-acting antivirals (DAAs); GLOBAL EPIDEMIOLOGY; B-VIRUS; INFECTION; RISK; HCC;
D O I
10.1186/s12885-021-08426-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in Africa. In Africa, the major causes of HCC include chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). Knowledge of the changes in the incidence of viral hepatitis-associated HCC over time and the factors responsible for such changes is key in informing policies for the prevention of viral hepatitis-associated HCC in Africa. Aim The study aimed to systematically summarize the changes in the prevalence of viral hepatitis among HCC patients and the overall effect of the prevalence of viral hepatitis on the incidence of HCC over the past four decades in Africa (1980-2019). Methods A literature search was conducted in MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Web of Science, and African wide web for articles published on viral hepatitis-associated HCC in Africa from 1980 to 2019. The abstracts of the articles were screened for eligibility and those meeting the inclusion criteria were retrieved and reviewed. Results A total of 272 studies were included in the analysis. Viral hepatitis-related HCC incidence changed by 1.17% (95% confidence interval (CI): 0.63-1.71, p < 0.001), 0.82% (95% CI: 0.45-1.18, p < 0.001), and 3.34% (95% CI: 2.44-4.25, p < 0.001) for every 1% change in the prevalence of HBV, HCV, and hepatitis D virus (HDV) respectively, per decade. The incidence of HBV-related HCC decreased by - 0.50% (95% CI: - 0.74 - - 0.25, p < 0.001) over the last 40 years, while HCV-related HCC increased. Conclusion Overall, the incidence of viral hepatitis-associated HCC has not declined, mainly due to no decline in the prevalence of HCV, HDV, and the high number of chronic hepatitis B carriers on the African continent. There is an urgent need for the allocation of resources for the implementation of treatment and preventive programs for HBV, HCV, HDV, and HCC in Africa. This systematic review is registered with PROSPERO (R), number CRD42020169723.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Systemic treatment of hepatocellular carcinoma: Past, present and future
    Esther Una Cidon
    [J]. World Journal of Hepatology, 2017, (18) : 797 - 807
  • [12] Hepatocellular Carcinoma: Its Past, Present, and Future Preface
    Reuben, Adrian
    [J]. CLINICS IN LIVER DISEASE, 2011, 15 (02) : XIII - XVI
  • [13] Targeted therapies in hepatocellular carcinoma: past, present, and future
    Gujarathi, Rushabh
    Franses, Joseph W.
    Pillai, Anjana
    Liao, Chih-Yi
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [14] THERAPY OF CHRONIC VIRAL-HEPATITIS - PAST, PRESENT, AND FUTURE
    HOOFNAGLE, JH
    JONES, EA
    [J]. SEMINARS IN LIVER DISEASE, 1989, 9 (04) : 231 - 234
  • [15] The African Review of Economics and Finance: Past, present, and future
    Obeng-Odoom, Franklin
    Mensah, Jones Odei
    Botha, Ferdi
    [J]. AFRICAN REVIEW OF ECONOMICS AND FINANCE-AREF, 2019, 11 (02): : 3 - 18
  • [16] Systemic Therapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
    Giglia, Jennifer L.
    Antonia, Scott J.
    Berk, Lawrence B.
    Bruno, Salvador
    Dessureault, Sophie
    Finkelstein, Steven E.
    [J]. CANCER CONTROL, 2010, 17 (02) : 120 - 129
  • [17] Gene expression profiling of hepatocellular carcinoma: past, present and future
    Lee, J. -S.
    Thorgeirsson, S. S.
    [J]. DISEASE PROGRESSION AND DISEASE PREVENTION IN HEPATOLOGY AND GASTROENTEROLOGY, 2006, 150 : 233 - 237
  • [18] Ablation therapy for hepatocellular carcinoma: past, present and future perspectives
    Niemeyer, David J.
    Simo, Kerri A.
    Iannitti, David A.
    McKillop, Iain H.
    [J]. HEPATIC ONCOLOGY, 2014, 1 (01) : 67 - 79
  • [19] Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future
    Stotz, Michael
    Gerger, Armin
    Haybaeck, Johannes
    Kiesslich, Tobias
    Bullock, Marc D.
    Pichler, Martin
    [J]. ANTICANCER RESEARCH, 2015, 35 (11) : 5737 - 5744
  • [20] The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future)
    Ishizaki, Yoichi
    Kawasaki, Seiji
    [J]. JOURNAL OF GASTROENTEROLOGY, 2008, 43 (01) : 18 - 26